Valerie Harper, best known for playing Rhoda Morgenstern on The Mary Tyler Moore Show and Rhoda, says she’s “absolutely cancer-free” over a year after announcing that she had terminal brain cancer.

Valerie Harper Is 'Cancer-Free'

"I'm absolutely cancer-free!" Harper told Closer Weekly. "My last scans have been positive, and my doctors are very happy. [The oncologist] looked at the scans and said, 'Oh my God, Valerie, this is very encouraging!' "

While her doctor is wary of telling the legendary comedic actress that she’s in remission, he’s more than happy with what the scans are showing. "My doctor doesn't use that term [remission],” said Harper. “He likes to say, 'I give you a treatment, and it's either responsive or non-responsive — and you are having a phenomenal response.'"

As part of her treatment regiment, Harper takes several pills in a “pulse does” – at one sitting, once per week.

Harper's Terminal Diagnosis

Harper, who last March refused to look at her terminal diagnosis as a death sentence, continues to be optimistic about her health and her life. "There may come a time when I'm not feeling good," she told the magazine. "But then again, that time may never come!"

"I'm now the poster child for not believing everything I'm told," Harper added.

When Harper revealed that she had leptomeningeal carcinomatosis in March 2013, she stated that her doctors expected that she had no more than three months to live. Since then, she’s fought the prognosis, going on to reunite with her Mary Tyler Moore costarsMary Tyler Moore, Cloris Leachman and Betty White – on Hot in Cleveland and competing on ABC’s Dancing With the Stars.

– Chelsea Regan

For More Valerie Harper News:

> ‘Mary Tyler Moore’ Reunion Featured On ‘Hot In Cleveland’ Finale

> ‘Dancing With The Stars’ Season 17 Cast Revealed

> Valerie Harper Appears On ‘The Doctors,’ Talks Brain Cancer Treatment

> Mary Tyler Moore Devastated By Valerie Harper’s Terminal Brain Cancer Diagnosis

Read more about:
UInterview

Article by UInterview

Leave a comment

Subscribe to the uInterview newsletter